Ceapro Inc.
TSXV:CZO Stok Raporu
This company is no longer active The company may no longer be operating, as it may be out of business. Find out why through their latest events.
See Latest Events Ceapro Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6 Ceapro yıllık ortalama 9.6% oranında kazançlarını artırırken, Chemicals sektöründe kazançlar growing at 17.8% annual. Gelirler yılda ortalama 2.6% oranında büyüyor .
Anahtar bilgiler Chemicals Sektör Büyümesi 4.5% Gelir büyüme oranı 2.6% Özkaynak getirisi -16.9% Net Marj -48.9% Son Kazanç Güncellemesi 31 Dec 2023
Yakın geçmiş performans güncellemeleri
Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.011 profit in 3Q 2022) Nov 30
Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.021 profit in 2Q 2022) Aug 31
First quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.026 profit in 1Q 2022) May 27
Full year 2022 earnings released: EPS: CA$0.056 (vs CA$0.037 in FY 2021) Apr 14
Third quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.011 in 3Q 2021) Nov 10
Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.009 in 2Q 2021) Aug 24
Tüm güncellemeleri göster
Ceapro Inc. Ordinary Shares to Be Deleted from OTC Equity Jun 08 Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction. Jun 05
Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.
Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.011 profit in 3Q 2022) Nov 30
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases Nov 29
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases Nov 28
Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.021 profit in 2Q 2022) Aug 31
The Returns At Ceapro (CVE:CZO) Aren't Growing Aug 09
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director Jun 08
First quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.026 profit in 1Q 2022) May 27
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases May 24
Full year 2022 earnings released: EPS: CA$0.056 (vs CA$0.037 in FY 2021) Apr 14
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets Dec 23
Third quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.011 in 3Q 2021) Nov 10
Ceapro Inc. Launches Next Phase of Scale Up for Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets Nov 08
Returns At Ceapro (CVE:CZO) Are On The Way Up Oct 15
Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers Oct 14
Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.009 in 2Q 2021) Aug 24
Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer Jul 13
Ceapro's (CVE:CZO) Returns Have Hit A Wall Jun 17
Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee Jun 08
High number of new directors May 31
First quarter 2022 earnings released: EPS: CA$0.026 (vs CA$0.007 in 1Q 2021) May 19
Insufficient new directors Apr 27
Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors Apr 20
Full year 2021 earnings released: EPS: CA$0.037 (vs CA$0.024 in FY 2020) Apr 14
Ceapro Inc., Annual General Meeting, Jun 01, 2022 Apr 02
Ceapro Appoints Ronnie Miller to its Board of Directors Mar 04
Ceapro Appoints Ronnie Miller to its Board of Directors Mar 03
Ceapro (CVE:CZO) Will Want To Turn Around Its Return Trends Nov 19
Third quarter 2021 earnings released: EPS CA$0.011 (vs CA$0.002 in 3Q 2020) Nov 19
Second quarter 2021 earnings released Aug 27
Be Wary Of Ceapro (CVE:CZO) And Its Returns On Capital Jul 20
Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as A Cholesterol-Lowering Agent May 27
Ceapro's (CVE:CZO) Robust Earnings Are Supported By Other Strong Factors May 27
First quarter 2021 earnings released May 22
Estimating The Fair Value Of Ceapro Inc. (CVE:CZO) Apr 29
Full year 2020 earnings released Apr 24
New 90-day low: CA$0.63 Mar 10
Will Ceapro (CVE:CZO) Multiply In Value Going Forward? Mar 01
Is It Too Late To Consider Buying Ceapro Inc. (CVE:CZO)? Feb 01
New 90-day high: CA$0.79 Jan 27
Estimating The Fair Value Of Ceapro Inc. (CVE:CZO) Jan 06
Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? Nov 28
New 90-day high - CA$0.84 Aug 19
Ceapro nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi TSXV:CZO Gelir, gider ve kazançlar (CAD Millions ) Tarih Gelir Kazançlar G+A Giderleri Ar-Ge Giderleri 31 Dec 23 10 -5 7 3 30 Sep 23 11 -3 6 3 30 Jun 23 13 -1 5 2 31 Mar 23 16 2 4 2 31 Dec 22 19 4 4 2 30 Sep 22 19 6 4 2 30 Jun 22 20 6 3 3 31 Mar 22 19 5 3 3 31 Dec 21 17 3 3 4 30 Sep 21 16 2 3 4 30 Jun 21 15 1 3 3 31 Mar 21 16 1 3 2 31 Dec 20 15 2 3 2 30 Sep 20 16 3 3 2 30 Jun 20 16 2 3 2 31 Mar 20 14 1 3 2 31 Dec 19 13 -1 3 2 30 Sep 19 14 -1 3 3 30 Jun 19 13 -1 3 3 31 Mar 19 13 -1 3 3 31 Dec 18 12 0 3 3 30 Sep 18 10 -2 4 2 30 Jun 18 12 -2 4 2 31 Mar 18 12 -1 3 1 31 Dec 17 13 -1 3 2 30 Sep 17 12 1 3 2 30 Jun 17 12 1 3 2 31 Mar 17 13 2 3 1 31 Dec 16 14 4 3 1 30 Sep 16 15 7 2 1 30 Jun 16 15 7 2 1 31 Mar 16 13 6 3 1 31 Dec 15 11 5 3 1 30 Sep 15 9 2 3 0 30 Jun 15 9 1 3 1 31 Mar 15 9 1 3 0 31 Dec 14 9 2 2 1 30 Sep 14 8 1 2 1 30 Jun 14 8 1 2 1 31 Mar 14 6 0 2 1 31 Dec 13 7 0 2 1 30 Sep 13 6 0 2 1 30 Jun 13 6 0 2 1
Kaliteli Kazançlar: CZO şu anda kârlı değil.
Büyüyen Kar Marjı: CZO şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CZO kârlı değildir, ancak son 5 yılda zararlarını yılda 9.6% oranında azaltmıştır.
Büyüme Hızlandırma: CZO 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: CZO kârlı olmadığından, geçmiş yıl kazanç büyümesinin Chemicals sektörüyle ( -39.7% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: CZO hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi 'ne ( -16.91% ) sahiptir.
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
